We report two unrelated families with multigenerational nonsyndromic intellectual disability (ID) segregating with a recurrent de novo missense variant (c.1543C>T:p.Leu515Phe) in the alkali cation/proton exchanger gene SLC9A7 (also commonly referred to as NHE7). SLC9A7 is located on human X chromosome at Xp11.3 and has not yet been associated with a human phenotype. The gene is widely transcribed, but especially abundant in brain, skeletal muscle and various secretory tissues. Within cells, SLC9A7 resides in the Golgi apparatus, with prominent enrichment in the trans-Golgi network (TGN) and post-Golgi vesicles. In transfected Chinese hamster ovary AP-1 cells, the Leu515Phe mutant protein was correctly targeted to the TGN/post-Golgi vesicles, but its N-linked oligosaccharide maturation as well as that of a co-transfected secretory membrane glycoprotein, vesicular stomatitis virus G (VSVG) glycoprotein, was reduced compared to cells co-expressing SLC9A7 wild-type and VSVG. This correlated with alkalinization of the TGN/post-Golgi compartments, suggestive of a gain-of-function. Membrane trafficking of glycosylation-deficient Leu515Phe and co-transfected VSVG to the cell surface, however, was relatively unaffected. Mass spectrometry analysis of patient sera also revealed an abnormal Human Molecular Genetics, 2019, Vol. 28, No. 4 599 N-glycosylation profile for transferrin, a clinical diagnostic marker for congenital disorders of glycosylation. These data implicate a crucial role for SLC9A7 in the regulation of TGN/post-Golgi pH homeostasis and glycosylation of exported cargo, which may underlie the cellular pathophysiology and neurodevelopmental deficits associated with this particular nonsyndromic form of X-linked ID.
Introduction
Syndromic and nonsyndromic forms of intellectual disability (ID) affect ∼1-2% of the human population and are characterized by pronounced limitations in both cognitive capabilities and adaptive behaviours covering various social and practical life skills (1, 2) . The underlying etiologies are diverse and complex, ranging from external influences (e.g. birth complications, malnutrition, infectious agents, substance abuse) to genetic perturbations (e.g. chromosomal abnormalities, epigenetic dysregulation, single-gene mutations), with the latter accounting for at least half of reported cases. The advent of next generation DNA sequencing approaches has greatly accelerated the pace of discovery of de novo mutations in known as well as in novel candidate genes associated with idiopathic ID (3) (4) (5) . To date, over 700 genes are linked to monogenic forms of ID (6) , with a disproportionate fraction (i.e. >100 genes) located on the X-chromosome (7) (8) (9) (10) (11) . These genes cover the gamut of biological processes, ranging from events in the nucleus such as genome replication, chromatin remodelling and transcription to extra-nuclear activities involving signal transduction, cytoskeletal dynamics, metabolism, vesicular trafficking, glycosylation and membrane excitability (12) (13) (14) (15) (16) (17) (18) (19) . It is not unexpected that mutations that impact on these critical cellular functions can profoundly affect central nervous system development and cognitive functioning (20, 21) .
In the present study, we describe a novel recurrent missense variant (NM 001257291.1:c.1543C>T:p.Leu515Phe) in the SLC9A7 gene (solute carrier family 9, member A7, also commonly called NHE7; OMIM 300368) located at chromosome position Xp11.3, which gives rise to a nonsyndromic form of ID, characterized by moderate to severe cognitive dysfunction, with brisk reflexes, hypotonia, muscle weakness and bilateral clinodactyly. SLC9A7 is widely transcribed with prominent expression in brain, skeletal muscle and various secretory tissues, including reproductive organs, adrenal, gastric, pancreas, pituitary, thyroid, salivary and mammary glands and encodes an alkali cation (Na + , K + )/proton (H + ) exchanger that resides in the Golgi, with preferential accumulation in the trans-Golgi network (TGN) and post-Golgi vesicles (22) (also, see human RNAseq expression data at https://www.ncbi.nlm.nih.gov/gene/84679 and https:// www.gtexportal.org/home/gene/SLC9A7). We investigate the effects of this mutation on the biosynthetic processing, stability and membrane trafficking of SLC9A7 and its impact on Golgi function.
Results

Clinical features and genetic analysis
We recently identified four males in an Australian (AU) family who presented with moderate to severe ID, significant speech delay, reserved personality, early hypotonia, muscle weakness, variable deep tendon reflexes, and bilateral clinodactyly ( Fig. 1A ; for additional description of the family history, see Supplementary Material). Females were clinically unaffected. Because of the male bias, X chromosome haplotype analysis was performed with 5 cM polymorphic markers in seven informative males (including the four males with ID and three unaffected male relatives). A shared haplotype was observed in all affected males between markers DXS8080 and DXS1196 covering a region of 41.8 Mbp between Xp11.3 and Xq21.1. The multipoint linkage data gave a logarithmic odds score of 1.49 (23) . The haplotypes in IV:2 and IV:5 indicated the disease-causing variant was on the paternally inherited allele in IV:2 assuming X-linked inheritance. As III:1 was reported to be of normal intelligence, any pathogenic variant was assumed to have occurred as a de novo mutation in IV:2. Using X-exome sequencing (11) of proband VI:1, we identified one variant of unknown significance in SLC9A7 (NM 001257291.1:c.1543C>T:p.Leu515Phe) located at chromosome position Xp11.3, a locus suggested to be enriched for genes linked to neurogenetic disorders (24) . This variant would be present in all expressed splice transcripts of SLC9A7 (SLC9A7v1: 726 amino acids, NCBI NM 001257291.1; SLC9A7v2, 725 amino acids, NCBI NM 032591.2; http://www.ncbi.nlm.nih.gov/).
Sanger sequencing confirmed the missense variant in VI:1, and subsequent segregation analysis showed that this variant was present in all affected males and also in IV:2. The variant was absent in IV:5, a sister of IV:2 who inherited the same X chromosome from their father. As IV:5 was negative for the variant, this suggested that the variant arose de novo on the paternal allele [i.e. their father's (III:1) X chromosome] of IV:2. In order to confirm this was the only novel coding or non-coding variant within this haplotype not shared by III:1 and the four affected males, we performed whole-genome sequencing of the affected male VI:1 and of IV:5, the putative non-carrier daughter of III:2. We extracted low-frequency hemizygous sequence variants present in VI:1 but not in IV:5, assuming a quality score for that base call of >60 in both samples. Of 23 906 hemizygous variant calls in this region in VI:1, the only unique variant reaching these thresholds was the previously identified c.1543C>T:p.Leu515Phe variant in SLC9A7. The presence of small copy number variations below the resolution of conventional cytogenetic array was examined using Lumpy (a probabilistic framework for discovering structural variants) (25) , with no variants overlapping coding genes identified in this region.
Case matching through colleagues and the Matchmaker Exchange portal (https://www.matchmakerexchange.org/) (26) identified a second family in the United States of America (family US) with the same variant in the proband IV:2 and his maternal uncle III:5 who presented with a similar phenotype including early hypotonia and gross motor delay, whilst the uncle was semi-independent as an adult ( Fig. 1B ; for clinical and family history, see Supplementary Material). The older photographs of males in both families (Fig. 1) show some similarities including a high anterior hairline, long face with a fine nose, deep nasolabial folds and slightly downturned angles of the mouth. Extraction of variant reads within 100 kb proximal and distal of SLC9A7 in both families showed that the variant was not present on a common haplotype and that these two families were unrelated (data not shown).
Amino acid Leu515 in SLC9A7 is highly conserved evolutionarily at the analogous positions of other human SLC9A isoforms (tolerating only isoleucine as a substitution) and is invariant Other male members of family US (II:5, II:10 and III:6) (shaded in gray) were diagnosed with developmental disabilities without a confirmed/known genetic etiology. Genetic analyses indicated that the common mutation is on distinct alleles, indicating that the families are unrelated.
in SLC9A7 orthologues from chimpanzees to zebrafish (Fig. 2) , suggesting that leucine at this position might be crucial for transporter structure and/or function. This observation is further supported by the fact that this region of the protein has a low residual variation intolerance score as measured by the missense tolerance ratio calculator (27) (Supplementary Material, Fig. S1 ). In keeping with this, the variant is absent in the gnomAD population control database (http://gnomad.broadinstitute.org/gene/ENSG00000065923) (28) .
Assessment of the biosynthesis, post-translational maturation and stability of SLC9A7
To evaluate the effects of the p.Leu515Phe (L515F) mutation on SLC9A7 function, the substitution was introduced into the cDNA of wild-type (WT) SLC9A7v1 that also contained an influenza virus hemagglutinin (HA) epitope at its C-terminus (simply referred to as WT HA and L515F HA ) for high-affinity immunological detection. For certain experiments, the SLC9A7 constructs were also fused at their C-terminus to mCherry fluorescent protein (i.e. WT ChFP and L515F ChFP ). The tagged WT and L515F constructs were then expressed in a subline of Chinese hamster ovary cells (AP-1 cells) to measure and compare their molecular and cellular properties, including the rates of biosynthesis and post-translational maturation, protein half-life, subcellular localization, Golgi pH homeostasis and function. This cell line was chosen for study because the level of endogenous SLC9A7 protein in AP-1 cells is very low or negligible, as revealed by western blotting and immunocytochemistry of AP-1 cells using an isoform-specific rabbit polyclonal antibody against SLC9A7 developed in our laboratory (Supplementary Material, Fig. S2 ). Hence, this cell line serves as an amenable model system to compare the properties of exogenous WT and L515F without the confounding presence of endogenous SLC9A7 protein.
SLC9A7, like other SLC9A isoforms, assembles as a homodimer and is purportedly glycosylated at a single N-glycosylation (Fig. 3B) . These results indicate that post-translational processing of L515F HA along the biosynthetic pathway is partially impaired compared to its WT HA counterpart.
To confirm the general nature of the oligosaccharide modifications of SLC9A7, AP-1 cells were transiently transfected with WT HA or L515F HA for 36 h, lysed in non-detergent buffers and post-nuclear supernatants were untreated or treated with either endoglycosidase H (Endo H), which cleaves only simpler asparagine-linked (N-linked) mannose-rich carbohydrate chains (i.e. core-glycosylated) but not more intricate fully glycosylated oligosaccharides, or peptide-N-glycosidase F (PNGase F), which removes all N-linked oligosaccharide structures. As shown in the immunoblots presented in Figure 3C , Endo H treatment reduced the size of only the core-glycosylated WT HA and L515F HA proteins, although the cleavage was incomplete under the recommended reaction conditions. In contrast, PNGase F subjected to SDS-PAGE and immunoblotting with a monoclonal anti-HA antibody (αHAm). SLC9A7 migrates as multiple bands: slower migrating high molecular weight bands representing the fully-glycosylated (fg, ∼270 kDa) and core-glycosylated (cg, ∼250 kDa) dimeric forms of the exchanger that do not fully dissociate under SDS-PAGE conditions and faster migrating fully-glycosylated (fg, ∼80-100 kDa), core-glycosylated (cg, ∼70 kDa) and unglycosylated (ug, ∼68 kDa) forms of the monomeric protein. removed all the N-linked oligosaccharide structures resulting in unglycosylated, faster migrating forms of SLC9A7. It was noted that the bands representing the dimeric forms of SLC9A7 were not evident in these blots, most likely due to their complete dissociation under the buffers conditions used for the glycosidase treatments.
As mentioned above, the biosynthesis data presented in Figure 3A show that the level of L515F HA protein expression is slightly reduced compared to WT HA . To determine whether the mutation affected the half-life of the transporter, a pulsechase experiment was carried out. AP-1 cells were transiently transfected with the SLC9A7 constructs for 24 h and then treated with cycloheximide to block new protein synthesis over a subsequent 24 h period. Cellular lysates were obtained at the indicated time points after cycloheximide treatment and analysed by western blotting and densitometry to monitor residual protein levels as a function of time. As shown in Figure 3D and E, both WT HA and L515F HA transporters exhibited rapid turnover rates, with the half-life (t 1/2 ) of L515F HA being slightly reduced compared to WT HA , though this difference did not reach statistical significance (L515F: 2.2 ± 0.43 h versus WT: 2.92 ± 1.52 h, P > 0.05).
Subcellular localization of SLC9A7
Previous studies (22, 32, 33) have shown that SLC9A7 localizes to the Golgi apparatus, with preferential accumulation in the TGN and post-Golgi vesicles and a minor fraction at the cell surface as it transients along the secretory pathway. We postulated that the observed reduction in post-translational processing and maturation of L515F could be due to impaired protein trafficking from the ER to the Golgi. To examine this possibility, AP-1 cells were transiently co-transfected with a TGN-specific marker, TGN46 tagged at its cytoplasmic-oriented C-terminus with emerald green fluorescent protein (GFP) (TGN46 EmGFP ) and SLC9A7 WT or L515F fused at their C-terminus to mCherry fluorescent protein (WT ChFP and L515F ChFP , respectively). The fluorescent cell images revealed that both WT ChFP and L515F ChFP were properly targeted to the TGN and post-Golgi vesicles as indicated by the high degree of signal overlap with TGN46 EmGFP (Supplementary Material, Fig. S3A ).
To determine whether the mutation altered surface expression of SLC9A7, we utilized a cell surface biotinylation assay (34) to selectively extract plasma membrane (PM) proteins of AP-1 cells transiently expressing WT HA or L515F HA at 24 and 48 h post-transfection. As shown in the immunoblots presented in Supplementary Material, Figure S3B , both fully and coreglycosylated WT HA and L515F HA were able to traffic to the cell surface at both time points. For the WT HA transporter, there was an enrichment of the fully glycosylated relative to the core-glycosylated species at the cell surface, whereas this ratio was reversed for the mutant L515F HA . Based on densitometric quantification of the signal intensities of SLC9A7 and the relative levels of protein in the total cell lysates (TCLs) and PM fractions, the amount of WT HA at the cell surface was estimated to be ∼3% of its total cellular expression at 24 h post-transfection. The normalized proportion of L515F HA transporters at the cell surface relative to its total cellular expression level was slightly reduced compared to WT HA at both time points (Supplementary Material, Fig. S3C ), but the differences were not statistically significant (two-sample Student's t-test, P > 0.05). This indicates that the mutation did not markedly alter the delivery of L515F HA to the PM.
Ratiometric measurement of pH in SLC9A7-containing endomembrane compartments
Progressive acidification of organelles along the biosynthetic pathway is known to be important for post-translational processing (e.g. glycan maturation, pre-prohormone cleavage), sorting and transport of nascent proteins (35, 36) . Earlier studies have established that the luminal pH of the ER is near neutrality and mirrors that of the cytoplasm (∼pH 7.1-7.2) (37,38), but becomes progressively more acidic within the Golgi cisternae (∼pH 6.4-6.6) (38-40), TGN (∼pH 6.0-6.4) (41-44) and secretory vesicles (pH 5.2-5.7) (43, 45) . Active accumulation of H + in organelles of the secretory pathway is achieved by the electrogenic vacuolartype H + -ATPase (46, 47) and is accompanied by parallel movements of counterions such as Cl − through various anion channels (48-51) that neutralize the buildup of positive charge that would otherwise decrease H + -ATPase activity. In addition, H + efflux pathways exist to counterbalance H + -ATPase-driven acidification in order to achieve an optimal acidic pH environment, though the precise mechanisms have yet to be fully resolved. Earlier studies described a Zn 2+ -inhibitable, voltage-sensitive H + conductance in the Golgi complex (52), but its molecular identity remains obscure. SLC9A7 (22) and SLC9A8 (53,54) have also been proposed as potential routes for electroneutral H + efflux in exchange for cytoplasmic K + (or Na + ) in the Golgi and postGolgi compartments. In support of this notion, overexpression of SLC9A8 in COS7 cells resulted in alkalinization of the midto trans-cisternae of the Golgi complex using a pH-sensitive probe targeted to those compartments (53) . However, a role for SLC9A7 in pH regulation of the Golgi has yet to be demonstrated empirically.
To selectively measure the intraluminal pH of only SLC9A7-containing endomembrane compartments, we inserted the cDNA for the ratiometric pH-sensitive GFP variant pHluorin2 (pH2) (55) in-frame within the first extracellular loop of WT and L515F ( pH2 WT and pH2 L515F), which would orient the fluorophore into the endomembrane lumen (illustrated in Fig. 4A ). This insertion did not appear to alter the biosynthesis or the subcellular distribution of either chimeric construct compared to their respective parental transporters in transiently transfected AP-1 cells (Fig. 4B, and data not shown) . The endomembrane pH (pH e ) of these compartments was measured using a fluorescence ratiometric image analysis (FRIA) technique (56) . For our pH e measurements, a laser-scanning confocal microscope was used to illuminate the cells alternately with 405 and 488 nm light and the emitted fluorescence was detected between 500 and 550 nm. To standardize the fluorescence ratio values (R488/405) as a function of pH e , calibration curves were performed in situ in AP-1 cells expressing pH2 WT by clamping the intraluminal pH e between 5.0 and 7.8 in K + -rich medium containing bafilomycin, an inhibitor of the vacuolar H + -ATPase and ionophores to equilibrate pH across membrane compartments and the extracellular solution. For each pH level, ∼25-50 vesicles or endomembrane clusters per cell were imaged and the average R488/405 values were calculated. The collected data were used to generate the calibration curve presented in Figure 4C . To compare the intraluminal pH e profiles of pH2 WT and pH2 L515F-containing endomembrane compartments, AP-1 cells were transiently transfected with each construct for 24 h and then incubated with cycloheximide for an additional 3 h to block new protein synthesis while allowing the existing pH2 WT and pH2 L515F to mature biosynthetically and accumulate in the TGN and postGolgi vesicles prior to measuring pH e (Fig. 4B) . During imaging, cells were maintained under physiological culture conditions in a microscope stage-top thermostatted incubation chamber [i.e. complete alpha-minimum essential medium (α-MEM) media buffered with 22 mm NaHCO 3 and equilibrated with 5% CO 2 and 95% air at 37
• C]. The distribution of pH2 WT and pH2 L515F-containing compartments (aggregate endomembrane pool from 15 cells) as a function of their pH e is presented in Figure 4D , with the median pH e value for pH2 L515F compartments shifted noticeably to more alkaline values compared to pH2 WT (median pH e 6.49 ± 0.02 versus 6.17 ± 0.03, respectively). Calculation of the mean steady state pH e of pH2 WT-containing endomembrane compartments per cell was 6.07 ± 0.03 (n = 31) cells] (Fig. 4E) , a value within the range of those previously documented for the TGN (pH 6.0-6.4) (41, 42, 44) . In contrast, the mean pH e of pH2 L515F-containing endomembranes was significantly more alkaline, i.e. pH e 6.57 ± 0.04 (n = 31, P < 0.001, two-sample Student's t-test).
Despite concordance with previous measurements of TGN pH e , insertion of pH2 into the first extracellular loop of SLC9A7 might have affected its catalytic properties, thereby distorting estimates of TGN pH e . Another potential shortcoming to using the pH2 SLC9A7 constructs as pH sensors is that TGN pH e cannot be assessed independently of exogenous SLC9A7 expression. To address these considerations, we constructed a separate TGN-specific pH-sensitive probe by fusing pH2 into the luminal-facing N-terminal domain of TGN46 ( pH2 TGN46). In transfected AP-1 cells, the signals of the pH2 TGN46 probe accumulated in a juxtanuclear compartment that overlapped those of WT ChFP and L515F ChFP (Supplementary Material, Fig. S4A) and responded appropriately to experimentally induced changes in intracellular pH (Supplementary Material, Fig. S4B ), thereby confirming the subcellular localization and fidelity of the TGN pH-sensing probe. TGN pH was then assessed in AP-1 cells co-transfected with pH2 TGN46 and ChFP, WT ChFP or L515F ChFP following the same experimental conditions used for the pH2 SLC9A7 probes. As shown in Figure 4F , the TGN pH e of cells separately expressing WT ChFP and L515F ChFP was 6.15 ± 0.06 and 6.58 ± 0.09, respectively, and corroborate our previous pH e measurements with pH2 WT and pH2 L515F (i.e. pH 6.07 ± 0.03 and 6.57 ± 0.04, respectively). Collectively, these results suggest that the exchange activity of the mutant L515F is altered, possibly enhanced, though the precise nature of the catalytic dysfunction remains to be determined. Curiously, and unexpectedly, there was no significant difference in resting TGN pH e of AP-1 cells which lack SLC9A7 expression (pH e 6.23 ± 0.12) compared to the WT ChFP -transfectants (pH e 6.15 ± 0.06). Because at steady state the rates of the H + pump and leak are identical, the finding that overexpression of WT SLC9A7 did not induce alkalization [i.e. cytoplasmic K + (or Na + ) influx in exchange for luminal H + efflux] above resting levels suggests that, at least in AP-1 cells, the rates of acidification mediated by endogenous vacuolar H + -ATPases and counterion conductances are not limiting and are sufficient to counter the additional H + efflux mediated by the exogenous WT exchanger, but are inadequate in the presence of the 'hyperactive' L515F mutant. However, further studies would be required to elucidate the precise underlying mechanism.
VSVG glycosylation and membrane trafficking
As mentioned above, the acidic environment of the Golgi is recognized as an important determinant of protein and lipid glycosylation and trafficking, as well as maintenance of Golgi morphology (51, (57) (58) (59) (60) . Given the observed impairment in glycosylation of the L515F mutant, we sought to determine whether other glycoproteins might be similarly affected when co-expressed with L515F. To this end, we performed a pulsechase experiment utilizing a temperature-sensitive variant (ts045) of the vesicular stomatitis virus G (VSVG) glycoprotein that was tagged with GFP (VSVG GFP ) (61, 62) . This glycoprotein variant misfolds and is retained in the ER when cells are incubated at 40
• C; however, upon shifting the temperature to 32
• C, the protein refolds to its proper conformation and is transported synchronously out of the ER to the Golgi and post-Golgi compartments. To monitor both glycosylation and cell surface trafficking of VSVG GFP , AP-1 cells were transiently transfected with VSVG GFP alone or in the presence of either WT HA or L515F HA at 37
• C. At 24 h post-transfection, some cell cultures were treated with the membrane-impermeable reagent N-hydroxysulfosuccinimydyl-SS-biotin to label PM proteins and lysed to examine VSVG GFP protein levels in the total lysates and cell surface fractions (control), whereas the remainder of the cell cultures were shifted to 40
• C in order to accumulate VSVG GFP in the ER. Next, cells in other culture dishes were biotinylated and lysed after 20 h of incubation at 40
• C, whereas the remainder were shifted to 32
• C for the indicated time points after being treated with cycloheximide (100 μg/ml) to prevent additional protein synthesis while allowing for synchronous export of the existing proteins from the ER to the Golgi and PM. As shown in the immunoblots presented in Figure 5A , shifting the temperature to 40
• C resulted in VSVG GFP remaining largely in its faster-migrating core-glycosylated state under all transfection conditions. At the permissive temperature of 32 • C, VSVG GFP was progressively glycosylated to its mature form in the absence or presence of WT HA . In contrast, addition of more complex N-glycans to VSVG GFP did not occur in cells co-expressing L515F HA . However, there were no apparent differences in cell surface delivery of VSVG GFP under each experimental condition, irrespective of it state of glycosylation, which peaked between 60 and 120 min and decreased thereafter (Fig. 5B) . These data suggest that L515F HA expression impaired VSVG GFP glycosylation, but had minimal effect on its trafficking to the PM. To validate the importance of acidification on complex glycosylation of VSVG GFP , we repeated the experimental protocol described above by co-transfecting VSVG GFP with WT HA in the absence or presence of 50 nM bafilomycin, a potent inhibitor of the vacuolar H + -ATPase that causes rapid alkalinization (within 10-20 min) of the Golgi as well as other acidic endomembrane compartments (42, 44) . As presented in Figure 5C , bafilomycin treatment prevented glycosylation of VSVG GFP in the presence of WT HA, a result similar to that obtained in untreated cells coexpressing L515F (shown in Fig. 5A ). As expected, pH e within the TGN/post-Golgi compartments rapidly alkalinized in the presence of bafilomycin using SLC9A7 pH2 WT as a pH-sensitive probe in companion cultures (Fig. 5D) . Collectively, these results indicate that proper acidification of the Golgi is critical for complex glycosylation of SLC9A7 as well as other secretory cargo.
To assess whether these in vitro findings have clinical relevance, we measured the N-glycosylation profile of serum transferrin in affected males of both families AU and US. This is a widely used clinical diagnostic assay to screen for N-linked congenital disorders of glycosylation (63) (64) (65) (66) . Normal transferrin contains two complex-type N-glycan sites, each comprised of a disialylated biantennary oligosaccharide chain, as the dominant species (i.e. the tetra-sialo form) and minor forms containing fucosylated or triantennary glycans (63) . Biochemical measurement of serum transferrin by capillary electrophoresis in three of the affected males in family AU failed to demonstrate any abnormality. However, in family US using a more sensitive affinity chromatography-mass spectrometry method (Mayo Clinical Laboratories, Rochester, Minnesota, USA, comparable assay not available in Australia) (67), we detected an abnormally high ratio of the tri-sialo/di-oligosaccharide chain that was most significant in affected male IV:2 (Table 1) , suggesting absence of a single sialic acid moiety.
Discussion
In this study, we identified and evaluated a novel recurrent missense variant (c.1543C>T, p.Leu515Phe) in the (Na + , K + )/H + exchanger gene SLC9A7 in two multigenerational Australian and American families with four and two affected males, respectively, who displayed moderate to severe ID that correlates with prominent expression of SLC9A7 mRNA in brain. This is the first report of a disease-causing variation in SLC9A7 and adds to a growing list of neurodevelopmental disorders associated with other SLC9A family members, including LichtensteinKnorr syndrome (SLC9A1) (68), Christianson syndrome (SLC9A6) (69, 70) , autism spectrum disorder (SLC9A6 and SLC9A9) (71, 72) and attention deficit hyperactivity disorder (SLC9A9) (73) (74) (75) .
Previous studies (22, 32, 33) have shown that SLC9A7 is sorted to the Golgi, with preferential accumulation in the TGN and post-Golgi vesicles that shuttle secretory cargo to the PM. In transfected Chinese hamster ovary AP-1 cells, we found that the L515F mutation did not significantly affect the transporter's protein stability or membrane trafficking. However, while the protein half-lives of WT and L515F were comparable (2.92 ± 1.52 h versus 2.2 ± 0.43 h, respectively), their turnover rates were rapid compared to the longevity (t 1/2 > 24 h) of the closely related recycling endosomal SLC9A6 isoform (∼68% identity) when overexpressed in the same cell line (76) . While speculative, the short half-life of SLC9A7 suggests that it may be preferentially targeted for degradation after its delivery to the PM rather than returned to the TGN, at least when expressed exogenously in this cell for 24 h at 37 • C. The temporal trafficking and oligosaccharide maturation of VSVG GFP along the biosynthetic pathway can be controlled in a temperature-sensitive manner. Shifting the temperature from 37-40 • C for 20 h causes the protein to accumulate in the ER. A subsequent temperature shift to 32 • C allows VSVG GFP to exit the ER and traffic along the secretory pathway (Golgi and PM). Cells were also treated with cycloheximide (100 μg/ml) to block further protein synthesis. TCL (A) and PM proteins isolated using a cell surface biotinylation protocol (B) were prepared at the indicated times and then subjected to SDS-PAGE and immunoblotting using a polyclonal GFP antibody (αGFP) to examine VSVG GFP glycosylation (cg, core-glycosylated; fg, fully glycosylated) or a mouse monoclonal anti-HA antibody (αHA) to detect SLC9A7 HA . For loading controls, calnexin (CANX) and Na + /K + -ATPase (ATP1A1) expression were measured as markers for TCL and PM fraction, respectively. Blots are representative of three independent experiments. (C) AP-1 cells were transiently co-transfected with VSVG GFP and WT HA and incubated as described above. Upon shifting the temperature to 32 • C, cells were treated with cycloheximide (100 μg/ml) and DMSO (control) or vacuolar H + -ATPase inhibitor bafilomycin (50 nm). Lysates line. This is unlike certain other TGN-associated membrane proteins such as TGN38/TGN46 (77, 78) or furin (79) (80) (81) , which constitutively recycle between the TGN and PM.
While the L515F substitution had minimal effects on SLC9A7 stability and sorting, the extent of N-linked complex glycosylation of the transporter was noticeably reduced. Likewise, addition of N-linked glycans to an exogenously expressed secretory cargo protein, VSVG glycoprotein, was largely abolished in cells expressing L515F compared to WT. These changes correlated with alkalinization of the TGN and associate compartments where SLC9A7 is expressed (i.e. pH e : L515F, 6.58 ± 0.09 versus WT, 6.15 ± 0.06). Curiously, overexpression of WT did not elevate the resting TGN pH e (i.e. pH e 6.23 ± 0.12) in native AP-1 cells lacking endogenous SLC9A7. The reason for this is unclear. We speculate (52) and SLC9A8 (53, 54) , though this remains to be established. In this regard, it is interesting to note that two unrelated families presenting with an isolated X-linked retinitis pigmentosa 2 (RP2) without associated ID were identified as having a contiguous gene deletion of both SLC9A7 and RP2 (MIM 312600) (82), suggesting that gain, rather than loss, of SLC9A7 function is associated with ID. In the case of the individuals with X-linked RP2, the loss of SLC9A7 may have been compensated for by the other Golgi H + efflux pathways mentioned above. The elevated TGN pH caused by the L515F variant ( pH ∼0.5 units) is pronounced and has the potential to disrupt normal Golgi function. For instance, the spatial and temporal regulation of glycan biosynthesis within the Golgi has been found to be exquisitely sensitive to intraluminal pH levels (83, 84) . Subtle increases in Golgi pH by only 0.2 units are sufficient to interfere with the most pH-sensitive step in N-oligosaccharide maturation of proteins, the terminal α-(2,3)-sialylation, by inducing mislocalization of the α-(2,3)-sialyltransferase into endosomal compartments (85) . More pronounced increases in Golgi pH cause additional mislocalization of other glycosyltransferases as well as altered Golgi morphology (83-85). As mentioned above, the diminished acidification of the TGN and associated compartments elicited by L515F impaired its own glycosylation as well as that of VSVG, but did not affect their subsequent trafficking to the cell surface. This pattern mimics earlier findings obtained with chemical agents that dissipate the H + gradient across the Golgi membrane and disrupt complex glycosylation of secretory cargo without impacting their delivery to the PM (86) (87) (88) (89) . Likewise, loss-of-function mutations in subunits of the V-ATPase (90, 91) or in Golgi pH regulator (GPHR), a Golgi-resident chloride channel (51), also thwart Golgi acidification and complex glycosylation. However, in these latter instances, they were also accompanied by disorganization of Golgi morphology and delayed trafficking of secretory cargo. The basis for these overlapping but differing outcomes are unclear, but may reflect the severity of regionalized pH dysregulation within the Golgi apparatus as well as differences in the molecular and cellular context. Collectively, these data indicate that defective Golgi/TGN acidification elicited by L515F could account for the observed protein hypoglycosylation.
Measurement of abnormal carbohydrate-deficient forms of circulating serum transferrin is used clinically as a diagnostic tool to screen for congenital disorders of glycosylation (63, 64) . In this regard, we examined the N-glycosylation pathway in three of the affected males in family AU by capillary electrophoresis of the various transferrin glycoforms, but did not find any abnormality typical of a classical carbohydrate glycoprotein deficiency (data not shown). However, in family US, a more sensitive mass spectroscopy test demonstrated a high trisialo/di-oligosaccharide chain ratio that suggests absence of a single sialic acid moiety. The difference in investigation reflects the reduced sensitivity of the capillary electrophoresis that is unable to quantify ratios of each species but acts as a baseline screening investigation. To date, further blood collection and testing has not been possible for the AU family, but we would assume a similar pattern would be demonstrated. The hyposialylated transferrin pattern bears similarity to other type II congenital disorders of glycosylation associated with mutations in genes associated with the conserved oligomeric Golgi complex (92) .
Glycosylation of proteins and lipids affects numerous cellular processes that are vital for embryonic and postnatal development (93) (94) (95) (96) . Hence, it is not unexpected that impaired N-glycan biosynthesis causes or contributes to the progression of various pathophysiological conditions, including cancers, muscular dystrophies, immune dysfunction and neurological disorders (66, 84, (97) (98) (99) (100) (101) . In the nervous system, polysialylation is essential for normal migration and differentiation of neural precursor cells (102, 103) , cell-cell and cell-matrix adhesion (104, 105) and synapse formation (106) . Within synapses, N-glycosylation of synaptophysin and synaptic vesicle protein 2 is required for optimal synaptic vesicle trafficking (107, 108) . Likewise, N-glycosylation promotes protein stability, membrane trafficking and/or activity of various neurotransmitter transporters (109-114) and voltage-gated ion channels (115) (116) (117) (118) (119) (120) (121) , which are crucial for membrane excitability and neurotransmission, and is necessary for cellular processes underlying learning and memory (122, 123) .
It should also be considered that the disease phenotype may be driven by disruption of other Golgi processes arising from defective SLC9A7 function. The activity of the TGN membraneassociated endoprotease furin, which catalyzes the cleavage of precursor proteins into their active forms, is pH-sensitive (124) and utilizes intraluminal K + as a regulatory cofactor (125) . Thus, SLC9A7 may play an indirect role not only in protein glycosylation but also potentially in the processing of pro-proteins or propeptides into their active forms that could affect central nervous system function.
In conclusion, this study implicates the organellar SLC9A7 isoform in nonsyndromic X-linked ID. We postulate that this unique, recurrent nonsynonymous variant (p.Leu515Phe) acts as a gain-of-function disease-causing mutation. Mechanistic studies in transfected cells revealed that expression of the mutant SLC9A7 results in diminished acidification of the TGN and associated endomembrane compartments that impaired post-translational glycosylation processing of SLC9A7 and ectopically expressed VSVG glycoproteins and was found to have a parallel affect in vivo. We postulate that optimal TGN pH and proper glycosylation of other proteins required for normal development and function of the nervous system might underlie this neuropathic phenotype. Further investigation will be required to determine the precise molecular and cellular mechanisms underlying this disorder.
Materials and Methods
Ethics approval and consent to participate
Genetic studies were approved by local ethics committees. Written informed consent was obtained for molecular genetic analysis and written permission was obtained before the publication of clinical data and photographs from all participants or their legal guardians.
DNA sequencing and alignment
DNA was extracted from blood (QIAamp DNA blood maxi kit, Qiagen, Hilden, Germany). X-exome sequencing and alignment was performed in one member of family AU IV:6 ( Fig. 1) as described by Hu et al. (11) . Subsequent whole-genome sequencing and alignment was performed on IV:6 and VI:1 as previously described (126) . Using genomic DNA from the proband and parents, the exonic regions and flanking splice junctions of the genome were captured using the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA). Massively parallel (NextGen) sequencing was done on an Illumina system with 100 bp or greater paired-end reads. Reads were aligned to human genome build GRCh37/UCSC hg19 and analysed for sequence variants using a customdeveloped analysis tool. Additional sequencing technology and variant interpretation protocol have been previously described (127) . The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/).
Affinity chromatography-mass spectrometry
This test was developed and its performance characteristics determined by the Mayo Clinic Laboratories (Rochester, MN, USA) in a manner consistent with the Clinical Laboratory Improvement Amendments (https://www.cms.gov/Regulations-andGuidance/Legislation/CLIA/index.html).
Antibodies and reagents
Mouse monoclonal anti-HA antibody was purchased from Covance Inc. (Berkeley, CA, USA). Rabbit polyclonal anti-GFP antibody was from Life Technologies. Mouse monoclonal anti-β-tubulin was from Sigma. Rabbit polyclonal anti-calnexin antibody (αCANX) was from Enzo Life Sciences, Inc. Mouse monoclonal anti-Na + /K + -ATPase α1 antibody was purchased from Affinity BioReagents (Thermo Fisher Scientific Inc.). The Emerald GFP-tagged TGN46 (TGN46 EmGFP ) was a gift from Michael Davidson (Addgene, mEmerald-TGNP-N-10 plasmid #54279). Horseradish peroxidase-conjugated secondary IgG antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). α-MEM, fetal bovine serum, penicillin/streptomycin and trypsin-EDTA were purchased from Wisent (Saint-Bruno, QC, Canada). All other chemical and reagents were obtained from BioShop Canada (Burlington, ON, Canada), Sigma or Fisher Scientific and were of the highest grade available.
Anti-SLC9A7 antibody production
To generate a polyclonal antibody specific for SLC9A7, a recombinant fusion protein of glutathione S-transferase (GST) and an isoform-specific C-terminal segment of human SLC9A7 (amino acids 551-582) was constructed by cloning into the BamHI/EcoRI sites of the pGEX-2 T vector (Amersham Biosciences). After sequence verification, the plasmid was transformed into the Epicurean Coli BL21-Codon Plus TM strain (Stratagene, Cedar Creek, TX, USA 
Recombinant DNA constructs and mutagenesis
The longest splice variant (v1) of SLC9A7 was engineered to contain the influenza virus HA epitope (YPYDVPDYAS) at its extreme C-terminus to create WT SLC9A7 HA . This construct was inserted into the HindIII and XbaI sites of the mammalian expression vector pcDNA3 (Invitrogen) and then used as a template to engineer the L515F missense substitution by polymerase chain reaction (PCR) mutagenesis. A monomeric Cherry fluorescent protein (ChFP) was also fused to the C-terminus of SLC9A7 WT and L515F (WT ChFP and L515F ChFP ). In separate constructs, the pH-sensitive GFP pHluorin2 (pH2) (55) was inserted in the first extracellular loop (at amino acid position M54) of WT and L515F SLC9A7 ( pH2 WT and pH2 L515F). Insertion of the different fluorescent protein tags in these positions did not alter the biosynthesis properties or cellular distribution of SLC9A7 compared to C-terminal HA-tagged versions of SLC9A7 (22) . The pHluorin2-TGN46 ( pH2 TGN46) was engineered by replacing GFP in the mammalian expression vector pAcGFP1-C1 (Clontech) with pHluorin2 between the NheI and XhoI sites. This new vector was named pAcpHluorin2-C1. Next, human TGN46 was inserted in-frame C-terminal to pHluorin2 between the KpnI and BamHI sites of pAcpHluorin2-C1. To ensure proper targeting of pH2 TGN46, the signal sequence of TGN46 (i.e. first 21 amino acids) was inserted N-terminal to pH2 TGN46 by PCR mutagenesis using the NheI and BamHI restriction sites. All constructs were sequenced to confirm that no additional mutations were introduced during PCR. The temperature-sensitive variant (ts045) of VSVG glycoprotein tagged with GFP was kindly provided by Dr John Presley (McGill University).
Cell culture and transfection
AP-1 cells (Chinese hamster ovary fibroblasts that lack PM NHE1) were grown to subconfluence in α-MEM supplemented with 10% fetal bovine serum, penicillin (100 units/ml), streptomycin (100 μg/ml) and 25 mm NaHCO 3 (pH 7.4). Plasmid DNA was transiently transfected into AP-1 cells using Lipofectamine2000 TM (Invitrogen) according to the manufacturer's recommended protocols. Cells were cultured in a humidified atmosphere of 5% CO 2 and 95% air at 37
• C (unless otherwise indicated).
Western blotting
For western blot analyses, AP-1 cells were grown in 3.5 or 10 cm dishes and transiently transfected with 2-5 μg of plasmid DNA encoding SLC9A7 HA WT or L515F constructs [along with VSVG GFP (5 μg) in some experiments] according to the manufacturer's recommended procedures. Cell lysates were prepared and analysed as previously described (29) .
Endoglycosidase treatment
To assess the glycosylation status of SLC9A7, AP-1 cells were grown in 10 cm dishes and then transiently transfected with SLC9A7 HA WT or L515F as described above. Thirty-six hours posttransfection, post-nuclear supernatants prepared and treated with Endo H (750 units, New England Biolabs, Mississauga, ON, Canada) or PNGase F according to the manufacturer's recommendations as previously described (29) . Treated samples were then diluted with 2-fold concentrated SDS-PAGE sample buffer, incubated on a rocker for 30 min at room temperature, briefly centrifuged and analysed by SDS-PAGE and western blotting with a mouse monoclonal anti-HA antibody.
Cell surface biotinylation
AP-1 cells transiently expressing SLC9A7 HA WT or L515F were cultured in 10 cm dishes to sub-confluence, placed on ice and washed twice with ice-cold phosphate-buffered saline (PBS) containing 1 mm MgCl 2 and 0.1 mm CaCl 2 , pH 8.0 phosphatebuffered saline containing calcium and magnesium (PBS-CM). Cells were then incubated at 4
• C for 30 min with the membraneimpermeable reagent N-hydroxysulfosuccinimydyl-SS-biotin (0.5 mg/ml; ThermoScientific, Rockford, IL, USA), and the biotinylated PM protein were extracted with a NeutrAvidin ® Agarose Resin slurry (Fisher Scientific, Whitby, ON, Canada) as previously described (29) . The proteins in the total lysates and surface fractions were resolved by SDS-PAGE and analysed by western blotting.
Measurement of SLC9A7 half-life
To determine the stability of SLC9A7 HA WT and L515F proteins, AP-1 cells were grown in 3.5 cm dishes and transiently transfected with WT or L515F constructs. Twenty-four hours posttransfection, cells were treated with cycloheximide (150 μg/ml) to inhibit new protein synthesis in α-MEM supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin for up to 24 h. At specific time points, cells were lysed, protein concentrations were measured and equal quantities of protein (30 μg) were subjected to SDS-PAGE and immunoblotting with a mouse monoclonal anti-HA antibody and rabbit polyclonal αCANX (as a loading control). The intensities of the bands were quantified by densitometry of X-ray films exposed in the linear range and analysed using ImageJ software. Data were modelled to an exponential decay using a fit function (y = A1 * exp(−x/t1) + y0).
Fluorescence confocal microscopy
AP-1 cells were cultured overnight on fibronectin-coated 18 mm glass coverslips and transiently co-transfected with a fluorescent marker to label the TGN compartment (TGN46 EmGFP ) and a monomeric ChFP-tagged SLC9A7 (SLC9A7 ChFP ) WT or L515F (0.4 μg each). Cells were then fixed 24 h post transfection with 4% paraformaldehyde for 20 min at room temperature and mounted onto glass slides. A Zeiss LSM 780 confocal microscope, equipped with a photomultiplier tube (PMT) detector and a 63×/1.4 NA oil immersion objective lens, was used to obtain the images. These images were then prepared and presented using Zeiss ZEN and CorelDraw TM X6 software.
Ratiometric measurement of intraluminal pH
AP-1 cells were grown overnight on FluoroDishes TM (World Precision Instruments, Inc.) coated with fibronectin/PBS (2 μg/ml, for 2-4 h at 37
• C). Cells were transfected with 1 μg DNA/dish of pH2 WT, pH2 L515F or pH2 TGN46 using Lipofectamine2000 reagent according to the manufacturer's instructions. Twenty-four hours after transfection, cells were incubated for 3 h with 100 μg/ml cycloheximide in complete medium to block de novo protein synthesis and allow the newly synthesized constructs to exit the ER. During imaging, cells were maintained under physiological culture conditions in a microscope stage-top incubator (i.e. complete α-MEM media buffered with 22 mm NaHCO 3 and equilibrated with 5% CO 2 and 95% air at 37 • C). Intraluminal pH was measured by single-cell FRIA (56), using a Zeiss LSM 780 confocal microscope, equipped with a PMT detector. Images were acquired with a 63×/1.4 NA oil immersion objective lens by sequential line scanning at 405 and 488 excitation wavelengths, with emission set at 500-550 for both channels. All cells were imaged in a heated chamber (37 • C) at 3× zoom, while the laser power, resolution, speed of scanning, digital gain and offset, pinhole opening and line averaging were identical for both channels. Average intensities of fluorescent puncta (0.3-3 μm in diameter) were obtained for both the 405 and 488 channels using the MetaXpress software (Molecular Devices, Downingtown, PA, USA) and 488/405 ratios were calculated. 
Statistical analyses
The data represent the mean ± the standard error of the mean (S.E.M.) and statistical analyses were performed using a twosample Student's t-test or one-way analysis of variance (ANOVA).
A minimum P-value of <0.05 was considered significant.
Supplementary Material
Supplementary Material is available at HMG online.
